- Home
- ERAS vs DHIL Comparison
ERAS vs DHIL Comparison
Compare ERAS & DHIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- DHIL
- Stock Information
- Founded
- ERAS 2018
- DHIL 1990
- Country
- ERAS United States
- DHIL United States
- Employees
- ERAS N/A
- DHIL N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- DHIL Investment Managers
- Sector
- ERAS Health Care
- DHIL Finance
- Exchange
- ERAS Nasdaq
- DHIL Nasdaq
- Market Cap
- ERAS 439.7M
- DHIL 384.0M
- IPO Year
- ERAS 2021
- DHIL 1995
- Fundamental
- Price
- ERAS $2.32
- DHIL N/A
- Analyst Decision
- ERAS Buy
- DHIL
- Analyst Count
- ERAS 6
- DHIL 0
- Target Price
- ERAS $3.83
- DHIL N/A
- AVG Volume (30 Days)
- ERAS 1.7M
- DHIL 30.7K
- Earning Date
- ERAS 11-11-2025
- DHIL 10-29-2025
- Dividend Yield
- ERAS N/A
- DHIL 4.25%
- EPS Growth
- ERAS N/A
- DHIL 21.42
- EPS
- ERAS N/A
- DHIL 17.58
- Revenue
- ERAS N/A
- DHIL $151,281,009.00
- Revenue This Year
- ERAS N/A
- DHIL N/A
- Revenue Next Year
- ERAS N/A
- DHIL N/A
- P/E Ratio
- ERAS N/A
- DHIL $8.11
- Revenue Growth
- ERAS N/A
- DHIL 6.29
- 52 Week Low
- ERAS $1.01
- DHIL $122.32
- 52 Week High
- ERAS $3.31
- DHIL $173.25
- Technical
- Relative Strength Index (RSI)
- ERAS 68.53
- DHIL 46.20
- Support Level
- ERAS $1.78
- DHIL $138.91
- Resistance Level
- ERAS $2.65
- DHIL $143.51
- Average True Range (ATR)
- ERAS 0.20
- DHIL 2.26
- MACD
- ERAS 0.05
- DHIL 0.17
- Stochastic Oscillator
- ERAS 68.34
- DHIL 41.71
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About DHIL Diamond Hill Investment Group Inc.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.